Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media

The Journal of Antimicrobial Chemotherapy
H DabernatA Scheimberg

Abstract

A multicentre, open-label, randomized study was performed in 501 out-patients with acute otitis media, aged 6-36 months, to study the impact of treatment with either cefixime suspension 8 mg/kg/day bd or co-amoxiclav suspension 80 mg/kg/day tds for 10 days on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae. Of 426 patients with nasopharyngeal cultures at entry to the trial, end of treatment and at follow-up visit (35 days after inclusion), significant changes in carriage of S. pneumoniae were observed. The proportion of penicillin-resistant S. pneumoniae was higher in the samples taken at the end of treatment and follow-up than in those taken at inclusion, while the total number of children with this microorganism was lower. The difference at the end of treatment was greater with co-amoxiclav than with cefixime. For H. influenzae the resistance rate remained steady while the number of children with this microorganism decreased. At follow-up there was no significant difference between the two groups in terms of nasopharyngeal positive culture for S. pneumoniae or H. influenzae. Despite these differences, successful clinical responses were similar at the end of treatment and at follow-up.

Citations

May 26, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B DunaisC Pradier
Apr 17, 2003·International Journal of Pediatric Otorhinolaryngology·Margaretha Foglé-HanssonAnn Hermansson
Sep 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E VaronR Cohen
Oct 26, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·F GhaffarG H McCracken
Mar 27, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M Lipsitch
Aug 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G V Doern
Aug 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D Steinke, P Davey
Nov 1, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George A SyrogiannopoulosNicholas G Beratis
May 6, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eric L Nuermberger, William R Bishai
Aug 10, 1999·The Pediatric Infectious Disease Journal·F GhaffarG H McCracken
Dec 6, 2001·The Pediatric Infectious Disease Journal·E R WaldA Hoberman
Sep 9, 2005·The Pediatric Infectious Disease Journal·Ron DaganEthan Rubinstein
Jan 25, 2005·The Pediatric Infectious Disease Journal·Philip ToltzisJeffrey L Blumer
Feb 19, 2000·Antimicrobial Agents and Chemotherapy·S I PeltonD Stalker
Jan 11, 2008·Journal of Clinical Microbiology·Koichi HashidaHideaki Suzuki
Apr 19, 2003·Journal of Clinical Microbiology·Henri DabernatPierre Dellamonica
Jan 17, 2003·Paediatric Drugs·Philippe Ovetchkine, Robert Cohen
Jun 1, 2014·Journal of the Pediatric Infectious Diseases Society·Jonathan ReismanThomas Hennessy
Oct 13, 2006·European Journal of Pediatrics·Alvaro Díaz ConradiUNKNOWN Spanish Pneumococcal Infection Study Network
Oct 16, 2004·Expert Review of Anti-infective Therapy·Susan V Smith, Ian M Gould
Aug 3, 2005·International Journal of Pediatric Otorhinolaryngology·Javier María CasellasDaniel Stamboulian
Jul 4, 2003·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Jae-Hoon Song
Jan 30, 2015·Frontiers in Cellular and Infection Microbiology·Yashuan ChaoAnders P Hakansson
Mar 1, 2018·Physiological Reviews·A P HakanssonD Bogaert
Sep 14, 2004·The Pediatric Infectious Disease Journal·Stephen I Pelton
Dec 2, 2005·American Journal of Epidemiology·Matthew H SamoreMerle A Sande
Apr 20, 2002·Current Opinion in Infectious Diseases·R CohenP Géhanno
Dec 23, 1999·The Pediatric Infectious Disease Journal·M B Harper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Itzhak Brook, Alan E Gober
Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Nkuchia M M'ikanathaEbbing Lautenbach
Current Opinion in Infectious Diseases
R CohenP Gehanno
© 2022 Meta ULC. All rights reserved